Search bioRxivSearch

Biology subjects

Breen, G.

Publications and source records attributed to Breen, G..

21 records · Page 2Linked to original sources

Whole genome linkage analysis in a large Brazilian multigenerational family reveals distinct linkage signals for Bipolar Disorder and Depression.

Both common and rare genetic variation play a role in the causes for mood disorders. Very large families pose unique opportunities and analytical challenges but may provide a way to identify regions and mutations associated with mood disorders. We identified a family with a high prevalence (~30%) of mood disorders in a rural village in Brazil, featuring decreasing age of onset over generations. The pattern of inheritance was complex with 32 Bipolar type I cases, 11 Bipolar type II and 59 recurrent and/or severe Depression cases in addition to other phenotypes. We enrolled 333 participants with DNA samples from a broader pedigree of 960 subjects for genotyping using the Affymetrix 10K array. Non-parametric linkage was carried out via MERLIN and parametric with both MERLIN and MCLINKAGE. We exome sequenced a subset of the family (n=27) in order to identify rare variation within the linkage regions shared by affected family members. We identified four genome wide significant and four suggestive linkage regions on chromosomes 1, 2, 3, 11 and 12 for different phenotype definitions. However, no region received strong joint support in both the parametric and non-parametric analyses. Exome sequencing revealed potential deleterious variants in 11p15.4 for MDD and 1q21.1-1q21.3 and 12p23.1-p22.3, implicated in cell signaling, adhesion, translation and neurogenesis processes. Overall, our results suggest promising, but not definitive or confirmed evidence, that rare genetic variation contributes to the high prevalence of mood disorders in this multi-generational family. We note that a substantial role for common genetic variation is likely given the strength of the linkage signals observed.\n\nThe World Health Organisation reports depression and bipolar disorder as the second and seventh most important causes of years lost due to disability worldwide[1]. The heritability of bipolar disorder is between 60-90% with a lower but still substantial heritability for major depression (40-45%) [2]; [3]. First-degree relatives of bipolar disorder probands have a 5-10 fold increase in risk of developing the illness compared to relatives of controls but also show a three fold increase in unipolar depression, indicating that bipolar disorder does not \"breed true\" [4]. Large collaborative genome-wide association studies (GWAS) have uncovered several common genetic variants of small effect [5]. Genomewide estimates of heritability suggest that up to 60% of the genetic risk is contributed by common variants [6]. Overall, the current picture for bipolar disorder (and almost all complex traits) is a genetic architecture formed of both common and rare variants.\n\nLinkage studies have been pursued on the basis that there may be variants of greater effect shared between and within affected families. However these studies have usually focused on collections of comparatively small families or sib pairs and few consistent findings have emerged [7]. Large multigenerational families (e. g. of >30 affected individuals) theoretically offer a powerful means for mapping complex disease loci that are individually rare but common in a single family. These loci may be more highly penetrant and of larger effect than loci found with GWAS [8]. Here we report the results of the Brazilian Bipolar Family (BBF) study on a five-generation family of 639 members of which 333 were enrolled in the current analyses. Our objectives were to perform a linkage analysis with genome coverage and try to identify new genes/mutations related to bipolar and other mood disorders in the family. Here we report our findings and preliminary results of sequencing of linkage regions.

genetics

Applying polygenic risk scoring for psychiatric disorders within a family context

We aim to investigate the application of polygenic risk scoring within a family context. Polygenic risk profiles could aid in unraveling the role that common variation confers on disease risk within a pedigree that would have traditionally been viewed through the prism of monogenic inheritance only. We illustrate our discussion by analyzing polygenic risk scores for schizophrenia, major depressive disorder and bipolar disorder in a large pedigree (n~260) in which 30% of family members suffer from major depressive disorder or bipolar disorder. We apply polygenic risk scores to study patterns of assortative mating and anticipation, whereby it appears increased polygenic risk for psychiatric disorders is contributed by affected individuals who married into the family, resulting in an increasing genetic risk over generations in the family. This may explain the observation of anticipation in mood disorders, whereby onset is earlier and the severity of a disease increases over the generations of a family. Joint analyses of both rare and common variation may be the most powerful way to understand the familial genetics of mood and psychiatric disorders.

genetics

Pathways analyses of schizophrenia GWAS focusing on known and novel drug targets

Using successful genome-wide association results in psychiatry for drug repurposing is an ongoing challenge. Databases collecting drug targets and gene annotations are growing and can be harnessed to shed a new light on psychiatric disorders. We used GWAS summary statistics from the Psychiatric Genetics Consortium (PGC) Schizophrenia working group and a repositioning model for schizophrenia by testing the enrichment of antipsychotics. As sample size increases, schizophrenia GWAS results show increasing enrichment for known antipsychotic drugs, selective calcium channel blockers, and antiepileptics. Each of these therapeutical classes targets different gene subnetworks. We identify 162 Bonferroni-significant druggable genes, and 128 FDR-significant biological pathways related to neurons, synapses, genic intolerance, membrane transport, epilepsy, and mental disorders. These results suggest that, in schizophrenia, current well-powered GWAS results can reliably detect known schizophrenia drugs and thus may hold considerable potential for the identification of new therapeutic leads. Moreover, antiepileptics and calcium channel blockers may provide repurposing opportunities. This study also reveals significant pathways in schizophrenia that were not identified previously, and provides a workflow for pathway analysis and drug repurposing using GWAS results.

genomics